Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

Journal of Translational Medicine

Review

Doru T Alexandrescu¹  Constantin A Dasanu²  Michael J Gonzalez³  Boris Minev⁴  James Koropatnick⁵  Ron Hunninghake⁶  James A Jackson⁶  Nina A Mikirova⁶  Thomas E Ichim⁷  Neil H Riordan⁷  Jorge R Miranda-Massari⁸  Brandon Luna⁹  Vladimir Bogin⁹  Boris Markosian⁹  Todd Braciak^1,10  R Brian Stevens^1,11  Janis Ancans^1,12  Chien-Shing Chen^1,13 

[1] Department of Experimental Studies, Georgetown Dermatology, 3301 New Mexico Ave, 20018, Washington, DC, USA;Department of Hematology and Oncology, University of Connecticut, 115 North Eagleville Road, 06269, Hartford, Connecticut, USA;Department of Human Development, Nutrition Program, University of Puerto Rico, Medical Sciences Campus, 00936-5067, San Juan, PR;Department of Medicine, Moores Cancer Center, University of California San Diego, 3855 Health Sciences Dr, 92121, San Diego, California, USA;Department of Microbiology and Immunology, and Department of Oncology, Lawson Health Research Institute and The University of Western Ontario, 1151 Richmond Street, N2G 3M5, London, Ontario, Canada;Department of Orthomolecular Studies, Riordan Clinic, 3100 N Hillside, 67210, Wichita, Kansas, USA;Department of Orthomolecular Studies, Riordan Clinic, 3100 N Hillside, 67210, Wichita, Kansas, USA;Department of Regenerative Medicine, Medistem Inc, 9255 Towne Centre Drive, 92121, San Diego, California, USA;Department of Pharmacy Practice, University of Puerto Rico, Medical Sciences Campus, School of Pharmacy, 00936-5067, San Juan, PR;Department of Regenerative Medicine, Medistem Inc, 9255 Towne Centre Drive, 92121, San Diego, California, USA;Department of Regenerative Medicine, Medistem Inc, 9255 Towne Centre Drive, 92121, San Diego, California, USA;Department of Immunology, Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, 92121, La Jolla, California, USA;Department of Surgery, Microbiology, and Pathology, University of Nebraska Medical Center, 42nd and Emile, 86198, Omaha, Nebraska, USA;Department of Surgery, University of Latvia, 19 Raina Blvd, 1586, Riga, LV, Latvia;School of Medicine, Division of Hematology and Oncology, Loma Linda University, 24851 Circle Dr, 92354, Loma Linda, California, USA;

关键词: Ascorbic Acid;    Systemic Inflammatory Response Syndrome;    Neopterin;    Multi Organ Failure;    Ascorbic Acid Level;   

DOI  :  10.1186/1479-5876-9-25

 received in 2010-12-13, accepted in 2011-03-04,  发布年份 2011

来源: Springer

【 摘 要 】

The history of ascorbic acid (AA) and cancer has been marked with controversy. Clinical studies evaluating AA in cancer outcome continue to the present day. However, the wealth of data suggesting that AA may be highly beneficial in addressing cancer-associated inflammation, particularly progression to systemic inflammatory response syndrome (SIRS) and multi organ failure (MOF), has been largely overlooked. Patients with advanced cancer are generally deficient in AA. Once these patients develop septic symptoms, a further decrease in ascorbic acid levels occurs. Given the known role of ascorbate in: a) maintaining endothelial and suppression of inflammatory markers; b) protection from sepsis in animal models; and c) direct antineoplastic effects, we propose the use of ascorbate as an adjuvant to existing modalities in the treatment and prevention of cancer-associated sepsis.

【 授权许可】

Unknown   
© Ichim et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.